Justin Bryans talks to Chemistry World
Justin talks about diseases of poverty, developing new therapeutics and treatments for Parkinson's disease. Visit the Chemistry…
Adding value to early stage IP
Mike Dalrymple, Director at MRC Technology, has written an article for The Innovation Handbook about adding value…
O2h provides multi-FTE -synthetic chemistry services to MRCT
MRCT translates cutting edge scientific discoveries into commercial products, two of which (Tysabri and Actemra) are already on the market. The MRCT Centre for Therapeutics Discovery works closely with the MRCT Intellectual Property and Business Development Division and is rigorous in the selection of well‐defined and characterised targets, and considers novelty, validation and ‘druggability’. In addition, the group works on targets where there is a clear strategy for progression and development.
MRCT’s call for targets
A major centre created by the Medical Research Council (MRC) and MRC Technology (MRCT) in order to fast-track the discovery and development of novel drugs, opens its first call for targets today. The MRCT Centre for Therapeutics Discovery (CTD), based in London, is seeking small molecule drug discovery and therapeutic antibody targets from academic researchers.
Collaboration between Georg-August-University Göttingen, Universitätsmedizin, the University of Regensburg and MRCT
The collaboration will focus on development of a novel therapy of inflammatory and immune diseases based on the depletion of inflammatory monocytes. The first targets will be rheumatoid arthritis (RA) and multiple sclerosis (MS).
DiscoveRX, GSK & MRCT collaborate to de-orphanise GPCRs
DiscoveRX, GSK & MRCT collaboration to de-orphanise GPCRs mentioned in an article about universities driving new technology…
Bicycle Therapeutics is new MRC spinout
The spin out is a new biotechnology company developing a novel technology platform for the creation of a new generation of biotherapeutics, has secured seed funding from Atlas Venture and Novartis Venture Fund. Bicycle Therapeutics combines the most desirable features of small molecules and biologics, to create highly specific and highly stable drugs.
DiscoveRX GSK and MRCT collaborate to deorphanise GPCRs
The three way alliance aims to seek out natural substances that bind to G-protein-coupled receptors (GPCRs). Through the identification of the natural ligand for these receptors it is anticipated that this work will identify and validate new drug targets that could ultimately help develop new therapies, as compounds that modulate GPCRs are already the basis of many licensed medicines.
Centre for Therapeutics Discovery
A major centre to fast-track the discovery and development of novel drugs will be created by the Medical Research Council (MRC) and MRC Technology (MRCT).